For carbamazepine, HLA-B*15:02 has been strongly associated with SJS/TEN in Asian populations [68–71], thus the European Medicines Agency and U.S. Food and Drug Administration recommend its screening before starting a treatment with this drug in at-risk populations [72]. Here, HLA-B is linked to toxic epidermal necrolysis.